Article
Virology
Samuel Hardy, Ben Jackson, Stephen Goodbourn, Julian Seago
Summary: The N-protein of CSFV has been found to inhibit dsRNA-induced apoptosis and antagonize apoptosis triggered by SeV by interacting with IRF3 and Bax. This interaction not only contributes to the antagonism of type I IFN by N-pro, but also plays a role in dsRNA-mediated mitochondrial apoptosis.
JOURNAL OF VIROLOGY
(2021)
Article
Oncology
Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak, Katerina Machova Polakova
Summary: This study revealed that somatic mutations acquired through treatment with imatinib are a prevalent mechanism of resistance development in CML cells. Mutations were associated with increased expression of genes involved in DNA repair pathways, leading to genomic instability.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Daniele Caracciolo, Caterina Riillo, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone
Summary: Cancer onset and progression result in high levels of DNA damage, with error-prone DNA repair pathways promoting genomic instability that leads to the appearance of cancer hallmarks through progressive genetic aberrations in tumor cells. This provides a potential target for precision oncology through the inhibition of Alternative Non-Homologous End Joining (Alt-NHEJ) as a new cancer vulnerability.
Article
Cell Biology
Qi Liu, Luis Palomero, Jade Moore, Ines Guix, Roderic Espin, Alvaro Aytes, Jian-Hua Mao, Amanda G. Paulovich, Jeffrey R. Whiteaker, Richard G. Ivey, George Iliakis, Daxian Luo, Anthony J. Chalmers, John Murnane, Miquel Angel Pujana, Mary Helen Barcellos-Hoff
Summary: The study reveals that TGF-beta signaling controls genomic stability by regulating the DNA damage response and inhibiting Alt-EJ gene expression. Tumors classified as low TGF-beta and high Alt-EJ show more genomic alterations and increased sensitivity to genotoxic therapy, suggesting potential therapeutic implications for targeting these pathways in cancer treatment.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Cell Biology
Wanyu Bai, Guangchao Zhu, Jiejie Xu, Pingyue Chen, Feilong Meng, Hongman Xue, Chun Chen, Junchao Dong
Summary: The study reveals a critical role of the flap endonuclease XPF-ERCC1 in A-EJ and oncogenic translocation in mouse B cells during class switch recombination (CSR). XPF-ERCC1SLX4 complex helps in achieving CSR in B cells, while deficiency of DNA ligase 4 and XPF-ERCC1 leads to impaired class switching process. ERCC1 plays an important role in resolving 3' single-stranded DNA flaps.
Article
Oncology
Zijing Lin, Jianping Gong, Guochao Zhong, Jiejun Hu, Dong Cai, Lei Zhao, Zhibo Zhao
Summary: This study investigated the relationship between alternative splicing events and cholangiocarcinoma, constructing a prognostic signature with six AS events. The research identified CDK11A as a negative regulator of survival-associated AS events and found that patients with high AS risk score may benefit more from immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Qiuying Ding, Zhengping Hou, Zhibo Zhao, Yao Chen, Lei Zhao, Yue Xiang
Summary: In this study, a prognostic signature reflecting genomic instability and overall survival (OS) of colorectal cancer (CRC) patients was constructed by analyzing splicing profiles, somatic mutations, and other related information. This signature showed good predictive performance for OS and could be used for clinical stratification and prognosis prediction. The study also identified splicing factors associated with OS and verified their roles in cell proliferation and migration.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Goodwin G. Jinesh, Andrew S. Brohl
Summary: Metastasis is a crucial event that worsens the prognosis of cancer patients. Understanding the pathways of metastasis is essential for the treatment of metastatic cancers, as these pathways contribute to drug resistance and immune evasion/suppression. This article discusses the details of two distinct but overlapping pathways of metastasis, namely the EMT pathway and the BMW pathway, and compares their roles in driving the process of metastasis.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Review
Medicine, Research & Experimental
Yao Qin, Pu Kuang, Ting Liu
Summary: Venetoclax combined with hypomethylating agents or low-dose cytarabine may be an effective and well-tolerated treatment option for untreated AML patients who cannot tolerate intensive chemotherapy. A meta-analysis of four clinical trials showed higher complete remission rates and median overall survival time in this treatment combination, with common adverse events including nausea, diarrhea, and hypokalemia.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.
CLINICAL CANCER RESEARCH
(2022)
Article
Endocrinology & Metabolism
Yushan Cui, Fangfang Wang, Danfeng Zhang, Jingcao Huang, Yan Yang, Juan Xu, Yuhan Gao, Hong Ding, Ying Qu, Wenyan Zhang, Weiping Liu, Ling Pan, Li Zhang, Zhigang Liu, Ting Niu, Ting Liu, Yuhuan Zheng
Summary: This study found that estrogen cell signaling negatively regulated multiple myeloma bone disease (MMBD) through the regulation of the MAST4 gene.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Cell Biology
Fangfang Wang, Zhang Dan, Hongmei Luo, Jingcao Huang, Yushan Cui, Hong Ding, Juan Xu, Zhimei Lin, Yuhan Gao, Xinyu Zhai, Yan Yang, Ying Qu, Li Zhang, Fengjiao Chen, Qiang Wang, Xin Wang, Yu Feng, Ting Liu, Qing Yi, Ting Niu, Yuhuan Zheng
Summary: Drug-resistance is a major problem in multiple myeloma (MM) patients. This study reveals that activated-leukocyte-cell-adhesion-molecule (ALCAM) regulates MM side population (SP)-mediated drug-resistance through the ALCAM-EGF/EGFR axis. EGFR activation promotes the SP ratio, while ALCAM inhibits EGFR downstream signaling in MM cells. SP MM cells have a higher number of mitochondria and interference of mitochondrial function inhibits SP-genesis. Combination therapy with an anti-MM agent and EGFR inhibitor gefitinib improves MM therapeutic efficacy and prolongs survival in MM-bearing mice.
CELL DEATH & DISEASE
(2022)
Letter
Hematology
Yao Qin, Kai Shen, Jiaqi Pu, Ting Liu, Hongbing Ma
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Wei Xu, Keshu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Kaiyang Ding, Jianfeng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jianda Hu, Chunyan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li
Summary: Orelabrutinib demonstrated significant efficacy and safety in patients with refractory or relapsed CLL/SLL, with an overall response rate of 92.5%. The median progression-free survival had not been reached at a 32.3-month median follow-up. Moreover, Orelabrutinib showed promising response in patients with high prognostic risks.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Kai Shen, Xiao Shuai, Jianjun Li, Jiazhuo Liu, Ting Liu, Ting Niu, Hongbing Ma
Summary: This case series study summarizes the clinical features, treatment, and prognosis of gastrointestinal chronic active EBV infection (CAEBV) with hemophagocytic lymphohistiocytosis (HLH). The study highlights the importance of early recognition and the possibility of salvage therapy combining surgery, novel therapeutic agents, and/or autologous hematopoietic stem cell transplantation (HSCT).
ANNALS OF HEMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Yu-Zu Guo, Yi Zhang, Qing Wang, Jun Yu, Qiu-Hong Wan, Jun Huang, Sheng-Guo Fang
Summary: Alligators are suitable for studying anti-aging molecular mechanisms because they have low adult mortality rates and no significant telomere shortening. Selection analyses have shown that certain genes in alligators have undergone positive selection, and ALT-related genes are expressed at higher levels, which may contribute to anti-aging strategies.
Article
Medicine, General & Internal
Jianying Zhou, Hang Zhang, Yao Qin, Ting Liu
Summary: We present a case of severe anemia in a 16-year-old male with complex hereditary spherocytosis (HS) and X-linked sideroblastic anemia (XLSA) caused by mutations in the spectrin beta (SPTB) and 5-aminolevulinic acid synthase (ALAS2) genes. Next-generation sequencing revealed double heterozygous mutations in exon 19 of the SPTB gene (c.3936G > A:p.W1312X) and exon 2 of the ALAS2 gene (c.37A > G:p.K13E). The mutations were confirmed by Sanger sequencing. The mutations in the SPTB and ALAS2 genes contribute to the more severe clinical phenotypes observed in this patient.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Lu Tang, Zhigang Liu, Tao Li, Tian Dong, Qiuhui Wu, Ting Niu, Ting Liu, Jie Ji
Summary: Through investigating 1091 articles, it was found that the PTCy prophylaxis regimen can reduce the incidence of aGVHD, decrease NRM and EBV-related complications, and achieve better OS compared to the ATG-based regimen. There was no significant difference between the two groups in cGVHD, RI, CMV reactivation, and BKV-related HC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji
Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren -Bin Zhao, Bin Zhang, Ya -Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu
Summary: Orelabrutinib demonstrates significant efficacy and tolerability in patients with relapsed or refractory mantle cell lymphoma, with a high overall response rate and median progression-free survival.
Article
Hematology
Lijuan Deng, Zhiming Li, Huilai Zhang, Haiwen Huang, Jianda Hu, Lihong Liu, Ting Liu, Jie Jin, Zunmin Zhu, Wenyu Li, Zhenqian Huang, Wenrong Huang, Keshu Zhou, Haiyan Yang, Mingzhi Zhang, Kaiyang Ding, Hui Zhou, Yu Hu, Yuerong Shuang, Junning Cao, Sujun Gao, Dengju Li, Zimin Sun, Qingyuan Zhang, Shuhua Yi, Chunyan Ji, Liansheng Zhang, Cheng Hou, Yue Du, Weige Wang, Renbin Zhao, Yuqin Song, Jun Zhu
Summary: Orelabrutinib, a new-generation oral drug, demonstrated high response rates and good tolerability in patients with marginal zone lymphoma (MZL).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Medicine, General & Internal
Xin-Xin Cao, Jie Jin, Cheng-Cheng Fu, Shu-Hua Yi, Wei-Li Zhao, Zi-Min Sun, Wei Yang, Deng-Ju Li, Guo-Hui Cui, Jian-da Hu, Ting Liu, Yong-Ping Song, Bing Xu, Zun-Min Zhu, Wei Xu, Ming-Zhi Zhang, Ya-Min Tian, Bin Zhang, Ren-Bin Zhao, Dao-Bin Zhou
Summary: Orelabrutinib has shown good efficacy and manageable safety profiles in patients with relapsed or refractory Waldenstrom's macroglobulinemia (R/R WM). The primary endpoint of this prospective study was to evaluate the major response rate (MRR) of orelabrutinib, which was found to be 80.9%, with an overall response rate of 89.4%.
Article
Hematology
Hongsheng Zhou, Qingsong Yin, Jie Jin, Ting Liu, Zhen Cai, Bin Jiang, Dengju Li, Zimin Sun, Yan Li, Yanjuan He, Liping Ma, Sujun Gao, Jianda Hu, Aili He, Xin Du, Daihong Liu, Xiaohong Zhang, Xiaoyan Ke, Junling Zhuang, Yue Han, Xiaoqin Wang, Yuqi Chen, Paul Gordon, Dong Yu, Gerhard Zugmaier, Jianxiang Wang
Summary: This Chinese registrational study evaluated the safety and efficacy of Blinatumomab in Chinese adults with Ph- R/R BCP-ALL. The results showed that Blinatumomab had comparable efficacy and safety in these heavily pre-treated patients as compared to those in global clinical trials.